



Media Contact:

Carol Berry

Chief Business Officer, SVP

Caprion, Inc.

cberry@caprion.com

514.360.3600

Caprion to Present Case Study on Role of Immune Monitoring in Pre-Clinical Development and Phase I/II Trials at ImVac Summit

Montreal, Canada - August 6, 2014—Caprion announced today that its immune monitoring business unit, ImmuneCarta®, will present case studies demonstrating how immune monitoring and profiling tools provide crucial insight into the immune system’s role in bolstering the effectiveness of immunotherapies and vaccines. The Immunotherapies and Vaccine Summit (ImVacS) will be held on August 11-14, in Boston, MA.

Presentation Title: Immune Profiling during Pre-clinical Development and in Phase I/II clinical Trials

Thursday, August 14th, 3:30 PM

Conference Track: Target Discovery for T Cell Therapy

The presentation will include discussion of how flow cytometry-based immune monitoring assays reveal clinical and immunological response relationships, and identify predictive biomarkers of immune protection. Information will be presented by Yoav Peretz, Ph.D., Scientific Director for ImmuneCarta.

Martin LeBlanc, President and CEO of Caprion, commented, “We are pleased with the growing number of our pharmaceutical and biotech partners who are accessing our deep immune monitoring expertise and assays to advance their immuno-therapeutic programs. Our integrated offering of established and customized multi-parametric assays deliver highly translational immunological insights at the discovery, pre-clinical and clinical stages.”

About Caprion

Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its immune monitoring business unit, ImmuneCarta®, offers proprietary multiparametric flow cytometry for functional analyses of innate and adaptive immune responses. Caprion’s proteomics business unit, ProteoCarta®, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Caprion also leverages ProteoCarta® to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has

been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 10 years. Caprion, a privately-held company, is majority owned by Chicago Growth Partners. For more information, please visit www.caprion.com.